The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
The economic burden of diabetic retinopathy in Germany in 2002
Abstract
Background The aims of our study were to describe the costs associated with diabetic retinopathy (DR), and to evaluate its economic impact in Germany.Methods Forty-one German ophthalmologists, randomly selected from a physicians' database in Germany, provided information on adult Type 1 and Type 2 diabetic patients with DR (n = 207). This information included socio-demographics, clinical characteristics and resource use during the year 2002. National-level cost estimates were calculated, based on these results and the prevalence data on DR in Germany.Results This study found that costs associated with DR tend to increase as DR progresses, being highest in patients with proliferative DR and lowest in patients with mild, non-proliferative DR. The German statutory health insurance (Gesetzliche Krankenversicherung, GKV) covered two-thirds of the total costs paid by all the payers. The total cost of DR from a societal perspective was calculated at 3.51 euros bn for the year 2002, and from the GKV perspective amounted to 2.23 euros bn.Conclusions This study is the first comprehensive study to provide estimates of costs associated with DR in Germany. These costs were estimated to account for approximately 1.5% of the total health-care expenditure in 2002.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, the German study [53] considered three groups of patients (sizes ranging from 38 to 43 subjects) with varying levels of NPDR severity (from mild to severe) in their cost calculations, which tended to be higher in the case of severe NPDR ($1,178 per patient per annum), as opposed to mild and moderate NPDR ($243 and $478 per patient per annum respectively).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [53]
In the citing paper
“In terms of direct non-medical and indirect costs, they were estimated at the patient level in the German study [53] and tended to be lower in NPDR patients than PDR patients in both cases: $259 vs. $571 per patient per annum for direct non-medical costs and $427 vs. $1,344 per patient per annum for indirect costs related to the productivity loss in patients (Supplementary Table 6).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [53]
In the citing paper
“Annual direct medical costs ranged from $45 to $613 in NPDR patients and from $441 to $3,031 in PDR patients (Fig. 5 and Supplementary Table 6), suggesting direct medical costs associated with PDR were about 5.8 times higher than those associated with NPDR.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [53]
In the citing paper
“Annual direct medical costs ranged from $45 to $613 in NPDR patients and from $441 to $3,031 in PDR patients (Fig. 5 and Supplementary Table 6), suggesting direct medical costs associated with PDR were about 5.8 times higher than those associated with NPDR.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [53]
In the citing paper
“In terms of direct non-medical and indirect costs, they were estimated at the patient level in the German study [53] and tended to be lower in NPDR patients than PDR patients in both cases: $259 vs. $571 per patient per annum for direct non-medical costs and $427 vs. $1,344 per patient per annum for indirect costs related to the productivity loss in patients (Supplementary Table 6).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [53]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wilkinson, C. P., Ferris, F. L., Klein, R. E., Lee, P. P., Agardh, C. D., Davis, M., Dills, D., Kampik, A., Pararajasegaram, R., & Verdaguer, J. T. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00475-5 · Cited by 3,743
The Economic Burden of Major Adult Visual Disorders in the United States
Rein, D. B. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.12.1754 · Cited by 635
Revealing the cost of Type II diabetes in Europe
Jönsson, B. (2002) · Diabetologia · doi:10.1007/s00125-002-0858-x · Cited by 392
Kassenärztliche Bundesvereinigung
(1985) · Oncology Research and Treatment · doi:10.1159/000215622 · Cited by 306
The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study
Köster, I., von Ferber, L., Ihle, P., Schubert, I., & Hauner, H. (2006) · Diabetologia · doi:10.1007/s00125-006-0277-5 · Cited by 201
Federal Statistical Office, Germany
(2003) · Choice Reviews Online · doi:10.5860/choice.41-1312 · Cited by 196
The impact of diabetic retinopathy: perspectives from patient focus groups
Coyne, K. S. (2004) · Family Practice · doi:10.1093/fampra/cmh417 · Cited by 164
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
O’Brien, J. A., Patrick, A. R., & Caro, J. J. (2003) · BMC Health Services Research · doi:10.1186/1472-6963-3-7 · Cited by 120
Stock, S., Redaèlli, M., Wendland, G., et al. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01779.x · Cited by 64
(2003) · Springer eBooks · doi:10.1007/978-3-662-11173-4 · Cited by 48
Research works printed but not linked: 2
- Hörle S, Kroll P (2005) Evidence based medicine using the example of diabetic retinopathy treatment. Dtsch Arztebl 102(38):2570–2577 (in German)
- Rote Liste Service GmbH (2002) Rote Liste 2002. Editio Cantor, Aulendorf
Cited by
Diabetes expenditure, burden of disease and management in 5 EU countries
Kanavos, P. G., van den Aardweg, S., & Schurer, W. (2012) · Cited by 228
Burden of illness of diabetic macular edema: literature review
Chen, E., Looman, M., Laouri, M., Gallagher, M., Van Nuys, K., Lakdawalla, D., & Fortuny, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.482503 · Cited by 158
Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States
Smith, A. F., & Waycaster, C. R. (2009) · BMC Ophthalmology · doi:10.1186/1471-2415-9-13 · Cited by 135
Scanlon, P. H., Aldington, S. J., Leal, J., Luengo-Fernández, R., Oke, J. L., Sivaprasad, S., Gazis, A., & STRATTON, I. M. (2015) · Health Technology Assessment · doi:10.3310/hta19740 · Cited by 145
Current treatments in diabetic macular oedema: systematic review and meta-analysis
Ford, J. A., Lois, N., Royle, P., Clar, C., Shyangdan, D., & Waugh, N. R. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002269 · Cited by 127
Metadata
- Authors
- Happich, M., Reitberger, U., Breitscheidel, L., Ulbig, M., & Watkins, J.
- Affiliations
- Eli Lilly (Germany) (DE)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Breitscheidel, Lusine
- Venue
- Graefe's Archive for Clinical and Experimental Ophthalmology
- Published
- 2007-04-04
- Volume
- 246
- Issue
- 1
- Pages
- 151-159
- ISSN
- 0721-832X (ISSN-L)
- 1435-702X
- OpenAlex
- W2054763804
- Cited by
- 63
- References
- 16
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 8 · 2023: 9 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 2 · 2017: 3 · 2016: 2 · 2015: 2 · 2013: 2 · 2012: 3
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- diabetic retinopathy, economic burden, health care costs, type 1 diabetes, type 2 diabetes, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, statutory health insurance, health care expenditure, Germany
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Health Expenditures, Female, Germany, Health Services Research, Health Status, Health Surveys, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Retrospective Studies, Databases, Factual, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The economic burden of diabetic retinopathy in Germany in 2002. https://app.cochat.ai/papers/10.1007/s00417-007-0573-x
- The paper
- Happich, M., Reitberger, U., Breitscheidel, L., Ulbig, M., & Watkins, J. (2007). The economic burden of diabetic retinopathy in Germany in 2002. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-007-0573-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.